Fasching, PA and Kollmannsberger, B and Strissel, PL and Niesler, B and Engel, J and Kreis, H and Lux, MP and Weihbrecht, S and Lausen, B and Bani, MR and Beckmann, MW and Strick, R (2008) Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Journal of Cancer Research and Clinical Oncology, 134 (10). pp. 1079-1086. DOI https://doi.org/10.1007/s00432-008-0387-1
Fasching, PA and Kollmannsberger, B and Strissel, PL and Niesler, B and Engel, J and Kreis, H and Lux, MP and Weihbrecht, S and Lausen, B and Bani, MR and Beckmann, MW and Strick, R (2008) Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Journal of Cancer Research and Clinical Oncology, 134 (10). pp. 1079-1086. DOI https://doi.org/10.1007/s00432-008-0387-1
Fasching, PA and Kollmannsberger, B and Strissel, PL and Niesler, B and Engel, J and Kreis, H and Lux, MP and Weihbrecht, S and Lausen, B and Bani, MR and Beckmann, MW and Strick, R (2008) Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Journal of Cancer Research and Clinical Oncology, 134 (10). pp. 1079-1086. DOI https://doi.org/10.1007/s00432-008-0387-1
Abstract
The aim of this study was to correlate chemotherapy-induced nausea and vomiting (CINV) with commonly occurring single nucleotide polymorphisms (SNP) in the 5-hydroxytryptamine receptor 3 genes (HTR3). Women with breast cancer without previous chemotherapy were eligible for this prospective study. All patients received epirubicin, with or without cyclophosphamide, and preventive medication with ondansetron and dexamethasone. The patients documented every vomiting event on an hourly basis. Real-time polymerase chain reaction (PCR) analysis was performed for the following nonsynonymous SNPs: p.Y129S (HTR3B), p.K163N (HTR3C) and p.A405G (HTR3C). The overall proportion of patients (total n = 110) who reported vomiting in the first 24 h after chemotherapy was 31.8%. The variant genotype of K163N (HTR3C) was associated with vomiting, which occurred in 50.0% (P = 0.009). Polymorphisms in the HTR3C gene could serve as a predictive factor for CINV in patients undergoing moderately emetogenic chemotherapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Chemotherapy-induced nausea and vomiting (CINV); Single nucleotide polymorphism; Breast cancer; 5-HT3R; Pharmacogenomics; HTR3C |
| Subjects: | Q Science > QA Mathematics R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Science and Health Faculty of Science and Health > Mathematics, Statistics and Actuarial Science, School of |
| SWORD Depositor: | Unnamed user with email elements@essex.ac.uk |
| Depositing User: | Unnamed user with email elements@essex.ac.uk |
| Date Deposited: | 12 Dec 2011 11:41 |
| Last Modified: | 05 Dec 2024 18:58 |
| URI: | http://repository.essex.ac.uk/id/eprint/1756 |